CEPI, CSL and University of Queensland partner on COVID-19 vaccine candidate

The University of Queensland (UQ) has partnered up with CSL and the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate development, manufacturing, and distribution of a COVID-19 vaccine candidate its researchers pioneered earlier this year. The UQ COVID-19 vaccine will be combined with Seqirus’ adjuvant technology, MF59, to improve immune response, reduce the amount of antigen required for vaccines, and allow more doses to be manufactured quicker.